Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. These abnormal plasma cells accumulate and interfere with the production of normal blood cells, causing anemia, bone pain, kidney problems, and frequent infections. While traditional treatments like chemotherapy, stem cell transplants, and targeted therapies exist, relapsed or refractory cases often require more advanced interventions.
CAR-T Cell Therapy for Multiple Myeloma
CAR-T (Chimeric Antigen Receptor T-cell) therapy is an innovative immunotherapy designed to specifically target and destroy malignant plasma cells. In this treatment, a patient’s own T-cells are collected, genetically engineered to recognize myeloma cells, and reinfused into the body.
CAR-T therapy has demonstrated significant success in patients with relapsed or refractory multiple myeloma, providing new hope for those who have limited options with conventional treatments.
Why Choose China for CAR-T Therapy
China has become a global hub for CAR-T therapy, offering patients:
- Access to cutting-edge clinical trials and therapies
- Expert hematologists and oncology teams specializing in multiple myeloma
- State-of-the-art hospitals with advanced supportive care
- Shorter waiting times and cost-effective treatment for international patients
Potential Benefits
- Targeted elimination of myeloma cells
- Reduced reliance on chemotherapy
- Potential for long-term remission
- Personalized therapy using the patient’s own immune cells
Treatment Duration
The CAR-T therapy process generally takes 3–5 weeks, covering T-cell collection, genetic modification, reinfusion, and monitoring. Follow-up care is essential to manage side effects and ensure optimal outcomes.
